Moreover, other critical regulators of MM biology, like MYC, IRF4, or PRDM1, as well as BCL2 and TNFRSF17 (BCMA) [33–35], were also highly downregulated by combination treatment (Figure 5C). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.